About Curesponse
Curesponse is a company based in Rehovot (Israel) founded in 2018 by Guy Neev, Nancy Gavert, and Ravid Straussman. Curesponse has raised $14 million across 2 funding rounds from investors including aMoon and NCL. Curesponse offers products and services including cResponse™. Curesponse operates in a competitive market with competitors including Guardant Health, Natera, Foundation Medicine, ArcherDX and Strand Life Sciences, among others.
- Headquarter Rehovot, Israel
- Founders Guy Neev, Nancy Gavert, Ravid Straussman
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$14 M (USD)
in 2 rounds
-
Latest Funding Round
$8 M (USD), Series B
Nov 15, 2021
-
Investors
aMoon
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Curesponse
Curesponse offers a comprehensive portfolio of products and services, including cResponse™.
Evaluates cancer therapies on biopsies for accurate treatment predictions
People of Curesponse
Unlock access to complete
Unlock access to complete
Funding Insights of Curesponse
Curesponse has successfully raised a total of $14M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $8 million completed in November 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Curesponse
Curesponse has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include aMoon and NCL.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments in healthcare are focused on by aMoon.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Curesponse
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Curesponse
Investment portfolio details for Curesponse
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Curesponse
Detailed financials for Curesponse
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Curesponse Comparisons
Peer comparison for Curesponse
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Curesponse
Curesponse operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Natera, Foundation Medicine, ArcherDX and Strand Life Sciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
Detailed competitors of Curesponse
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Curesponse
Complete news archive for Curesponse
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Curesponse
Curesponse was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Curesponse is headquartered in Rehovot, Israel. It is registered at Rehovot, Central District, Israel.
Guy Neev is the current CEO of Curesponse. They have also founded this company.
Curesponse is a funded company, having raised a total of $14M across 2 funding rounds to date.
Founded in 2018 in Rehovot, Israel, Curesponse operates in the biotechnology sector, focusing on oncology. A proprietary tissue culture system is utilized to preserve cancer tissue, including vasculature and immune components, for studying tumor behavior in vivo. The cResponse test is offered, evaluating patient tumor samples from biopsies or surgeries against various treatments. This is integrated with genomic analysis to tailor therapies for individual cancer patients.
Curesponse's top competitors include Guardant Health, Strand Life Sciences and Sutro Biopharma.
Curesponse offers cResponse™.
Curesponse has 2 investors. Key investors include aMoon, and NCL.